OrganiGram Holdings Inc. OGI · NASDAQ
$0.94 +1.73% (+$0.02)
Summary
55 / 100 · Bulios Score
What speaks for it
- Out of every 100 CAD of revenue, 28 CAD is left as net profit.
- You pay 2.2 CAD for 1 CAD of yearly profit, little for its sector.
What to watch
- It missed profit estimates 6 times in the last 8 quarters.
- It reports a profit, yet spends more cash than it brings in.
- Revenue growth is slowing: 8.5% a year over the last 3 years against 16% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapToday you pay 2.2 CAD for 1 CAD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (CAD)
Diluted EPS (CAD)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 8.5% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 CAD of revenue goes
- Cost of sales 63 CAD
- Research and development 3.1 CAD
- Sales and administration 33 CAD
- Taxes and other -30 CAD
- Net profit 28 CAD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 CAD
Out of every 100 CAD of revenue, 28 CAD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 2
- Sell 1
No analyst has published a price target.
40% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- International Business To Business 69%
- Wholesale To Licensed Producers Revenue 24%
- Direct To Patient Medical Revenue 6.3%
- Other Revenue 0.4%
By region
The company reports no revenue by region.
International Business To Business brings in 69% of revenue.
Segments in detail